Monitoring Patients With Mild/Moderate Multiple Sclerosis
July 3rd 2024The key opinion leaders provide recommendations on the optimal frequency for evaluating disease progression in patients with mild to moderate MS, emphasizing effective monitoring methods and the most appropriate tools for best clinical practice.
Factors Guiding Treatment Selection in Adult Spinal Muscular Atrophy
Panelists explore critical considerations when choosing a treatment approach for treatment-naïve adult patients with spinal muscular atrophy (SMA), taking into account factors such as disease severity, patient preferences, and potential treatment outcomes.
Treatments Approved for Treatment of Spinal Muscular Atrophy
Key opinion leaders (KOLs) examine the mechanisms of action and other pertinent information regarding FDA-approved treatments for spinal muscular atrophy (SMA), sharing their perspectives on these therapies with a particular focus on the various modes of administration.
Assessing Long-Term Benefit of Eptinezumab for Chronic Migraine: Amaal Starling, MD, FAHS, FAAN
Published: July 1st 2024 | Updated: July 1st 2024The associate professor of neurology at Mayo Clinic College of Medicine discussed findings from a post-hoc analysis of the phase 3 PREVAIL study presented at AHS 2024 assessing eptinezumab in patients with chronic migraine. [WATCH TIME: 4 minutes]
Building a Vibrant Community of Neurology Educators: Tracey Milligan, MD, MS, FAAN, FANA, FAES
Published: June 30th 2024 | Updated: July 1st 2024The professor and chair of neurology at New York Medical College discussed her extensive involvement in neurology education and the recent efforts to enhance neurology education through various programs. [WATCH TIME: 5 minutes]
Previewing ALS Association’s Inaugural Nexus Conference: John Novak, MD, MS
June 28th 2024The director of the OhioHealth ALS Clinic and vice chair of the ALS Association Care Services Committee discussed the upcoming ALS Nexus Conference and how themes of the event align with the direction of clinical care. [WATCH TIME: 3 minutes]
Conversations With Patients About Mild/Moderate Multiple Sclerosis
The expert panel examines early multiple sclerosis (MS) and patients with mild MS even in later stages of the disease, emphasizing crucial information to convey to patients throughout their journey; faculty also explore cases where disease-modifying therapies (DMTs) may not be utilized.
Mild/Moderate Multiple Sclerosis in Patients of Different Races and Ethnicities
Multiple sclerosis (MS) specialists discuss their observations regarding variations in MS presentation and progression among patients of Different Races and Ethnicities
Advancements in Multidisciplinary Parkinson Disease Treatment: Michael Soileau, MD, FAAN
June 26th 2024The movement disorder specialist at Texas Movement Disorder Specialists talked about a comprehensive panel discussion that highlighted the evolution of Parkinson disease treatment. [WATCH TIME: 4 minutes]
Enhancing Hospital Care for Patients With Parkinson Disease: Patricia Clark, CNP
June 26th 2024The nurse practitioner at the Cleveland Clinic talked about a specialized program involving nurse practitioners that aims to improve inpatient care quality and safety for patients with Parkinson disease. [WATCH TIME: 5 minutes]
Raising Awareness on Insomnia, Asking Patients About Their Sleep: Eric Olson, MD
Published: June 26th 2024 | Updated: June 26th 2024In honor of Insomnia Awareness Night, the president of the American Academy of Sleep Medicine board of directors talked about increasing awareness of the sleep disorder for the clinical and patient community. [WATCH TIME: 6 minutes]
Amyloid and Non-Amyloid Advanced Therapeutics in Dementia: R. Scott Turner, PhD, MD, FANA, FAAN
June 25th 2024The director of the Memory Disorders Program at Georgetown University talked about newly approved anti-amyloid antibodies that show significant promise in slowing Alzheimer disease progression. [WATCH TIME: 5 minutes]
Managing Clinical Stability in Adults Spinal Muscular Atrophy Patients
Clinical experts in spinal muscular atrophy (SMA) address the issue of patient disengagement from healthcare services, which can occur due to a perceived lack of disease progression or stabilization, leading to undetected disease advancement and increased risk to patients, and provide recommendations for encouraging patients to re-engage with medical care.
Key Players in Transitioning Patients with SMA from Pediatric Care to Adult Health Care
Key opinion leaders (KOLs) further explore the transition of care from pediatric to adult healthcare systems for patients with spinal muscular atrophy (SMA), emphasizing the essential role of multidisciplinary support in ensuring a successful transition.
Disease-Modifying Therapies for Dementia in Movement Disorders: Charbel Moussa, MBBS, PhD
June 24th 2024The associate professor of neurology at Georgetown University Medical Center talked about disease-modifying therapies for movement disorder-related dementia that aim to address the underlying mechanisms of the disease. [WATCH TIME: 5 minutes]
Advanced Therapeutic Options for Parkinson Disease and Essential Tremor: Anvi Gadani, MD
Published: June 24th 2024 | Updated: July 24th 2024The assistant clinical professor of medicine at Medstar Georgetown University Hospital talked about her presentation at ATMRD where she covered various advanced therapies for managing Parkinson disease and essential tremor. [WATCH TIME: 5 minutes]